Cargando…

French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak

Detalles Bibliográficos
Autores principales:	Penel, N., Bonvalot, S., Minard, V., Orbach, D., Gouin, F., Corradini, N., Brahmi, M., Marec-Bérard, P., Briand, S., Gaspar, N., Llacer, C., Carrère, S., Dufresne, A., Le Cesne, A., Blay, J.Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society for Medical Oncology. Published by Elsevier Ltd. 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144615/ https://www.ncbi.nlm.nih.gov/pubmed/32278878 http://dx.doi.org/10.1016/j.annonc.2020.03.308

Ejemplares similares

Options thérapeutiques de prise en charge des sarcomes durant la pandémie COVID-19 : propositions du groupe sarcome français
por: Penel, Nicolas, et al.
Publicado: (2020)

Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas
por: Brahmi, M., et al.
Publicado: (2021)

Patterns of care and outcome of CIC‐rearranged sarcoma patients: A nationwide study of the French sarcoma group
por: Brahmi, Mehdi, et al.
Publicado: (2022)

Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)
por: Moreau-Bachelard, C., et al.
Publicado: (2022)

Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma
por: Dufresne, A., et al.
Publicado: (2020)

Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC
por: Kubicek, Pierre, et al.
Publicado: (2023)

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group
por: Khalifa, J., et al.
Publicado: (2015)

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)(†)
por: Bompas, E., et al.
Publicado: (2015)

Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC’s)
por: Bétrian, Sarah, et al.
Publicado: (2017)

The off-label use of targeted therapies in sarcomas: the OUTC’S program
por: Eberst, Lauriane, et al.
Publicado: (2014)

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
por: Fazel, Mina, et al.
Publicado: (2023)

A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
por: Cassier, P A, et al.
Publicado: (2013)

ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based case–control study—study protocol
por: Lacourt, Aude, et al.
Publicado: (2019)

Bone Sarcomas: From Biology to Targeted Therapies
por: Gaspar, Nathalie, et al.
Publicado: (2012)

Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma The European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study
por: Penel, N, et al.
Publicado: (2011)

Surgery in reference centers improves survival of sarcoma patients: a nationwide study
por: Blay, J -Y, et al.
Publicado: (2019)

Surgery in reference centers improves survival of sarcoma patients: a nationwide study
por: Blay, J -Y, et al.
Publicado: (2019)

Pregnancy in Women with Metastatic Sarcomas
por: Yazigi, Alexandre, et al.
Publicado: (2020)

The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group
por: Perrier, Lionel, et al.
Publicado: (2018)

Radiotherapy in bone sarcoma: the quest for better treatment option
por: Locquet, Marie-Anaïs, et al.
Publicado: (2023)

Efficacy and Safety of Adjuvant Radiotherapy in Re-excised Soft-tissue Sarcoma After Unplanned Resection
por: Allignet, Benoît, et al.
Publicado: (2023)

TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials
por: Nassif, Elise F., et al.
Publicado: (2021)

High-dose chemotherapy followed by whole lung irradiation in pulmonary relapse Ewing’s sarcomas: a retrospective multicenter study
por: Duverge, Loig, et al.
Publicado: (2022)

Trabectedin and its potential in the treatment of soft tissue sarcoma
por: Cassier, Philippe A, et al.
Publicado: (2008)

An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)
por: Kasper, B, et al.
Publicado: (2017)

Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT)
por: Brahmi, Mehdi, et al.
Publicado: (2020)

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
por: Blay, Jean-Yves, et al.
Publicado: (2013)

Genomic complexity in pediatric synovial sarcomas (Synobio study): the European pediatric soft tissue sarcoma group (EpSSG) experience
por: Orbach, Daniel, et al.
Publicado: (2018)

Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study
por: Brodowicz, Thomas, et al.
Publicado: (2020)

Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors
por: Dufresne, A., et al.
Publicado: (2023)

No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks’ Outcome?
por: Fayet, Yohan, et al.
Publicado: (2022)

Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies
por: Blay, J.-Y., et al.
Publicado: (2023)

Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials
por: Nassif, E.F., et al.
Publicado: (2022)

Very long‐term survivors among patients with metastatic soft tissue sarcoma
por: Carbonnaux, Mélodie, et al.
Publicado: (2019)

Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis
por: Debaudringhien, M., et al.
Publicado: (2022)

Impact of the coronavirus disease 2019 pandemic on sarcoma management in France: a 2019 and 2020 comparison
por: Penel, Nicolas, et al.
Publicado: (2023)

Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years
por: Basse, Clémence, et al.
Publicado: (2019)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)
por: Patrikidou, Anna, et al.
Publicado: (2020)

Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial
por: Brodowicz, Thomas, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9l9lsntoljqlapdj5o6fdsmmie